Login to Your Account



Two Strikes

Clavis Reviews 'Strategic Options' After Phase III Bomb

By Nuala Moran
Staff Writer

Tuesday, April 2, 2013
Clavis Pharma AS has been hit by the Phase III failure of elacytarabine, its lipid-enhanced version of cytarabine, in a 380-patient trial in advanced acute myeloid leukemia (AML).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription